An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-55
SponsorAffinia Therapeutics
About this trial
This is a Phase 1/2, open-label, dose-exploration and dose-expansion, clinical trial evaluating the safety, tolerability, pharmacodynamics, and preliminary efficacy of a single intravenous infusion of AFTX-201 in adults with dilated cardiomyopathy caused by a BAG3 gene mutation
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- AFTX-201
Treatment groups
22 Participants
are divided into 1 treatment groupLocations
2University of Miami Hospital and Clinics33136, MiamiFlorida, United States
Houston Methodist Hospital77030, HoustonTexas, United States
Sponsors and collaborators
Affinia Therapeutics
Lead sponsor
Source ClinicalTrials.gov